Product Details

Uniprot No.

Target Names

Alternative Names

Mitogen-activated protein kinase kinase kinase 7 (EC 2.7.11.25) (Transforming growth factor-beta-activated kinase 1) (TGF-beta-activated kinase 1), MAP3K7, TAK1

Species Reactivity

Human, Mouse

Immunogen

A synthesized peptide from human MAP3K7 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

2B12

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
FC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

MAP3K7, also known as TAK1 (TGF-beta-activated kinase 1), serves as a critical upstream kinase in multiple signaling cascades that regulate inflammation, immunity, and cell survival. This serine/threonine kinase integrates signals from diverse stimuli including TGF-beta, TNF-alpha, and Toll-like receptors, making it a central node in pathways governing NF-κB activation and MAPK signaling. Researchers investigating inflammatory diseases, innate immunity, or stress-responsive pathways will find MAP3K7 an essential target for understanding these interconnected cellular processes.

This recombinant monoclonal antibody, generated from clone 2B12 in rabbit host, offers the reproducibility that demanding experiments require. Because recombinant production ensures sequence-defined consistency between lots, you can confidently compare results across extended studies without the variability inherent to traditional hybridoma-derived antibodies. The affinity-chromatography purification further ensures high specificity for your target.

Validation data demonstrates reliable performance across multiple experimental platforms. In western blot applications, this antibody detects MAP3K7 in human cell lines including A431 and K562, as well as mouse samples such as NIH/3T3 cells and brain tissue lysate, confirming cross-species reactivity between human and mouse. The observed band at approximately 75 kDa runs slightly higher than the predicted 67 kDa molecular weight, a shift commonly attributable to post-translational modifications such as phosphorylation or glycosylation that are characteristic of active kinases. Flow cytometry validation in 786-O renal carcinoma cells demonstrates clear separation from isotype controls, supporting intracellular detection applications.

Whether you're mapping kinase signaling networks, investigating inflammatory pathway regulation, or characterizing TAK1's role in disease models, this antibody provides the consistency and validated performance your research demands.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity. Phosphorylates RIPK1 at 'Ser-321' which positively regulates RIPK1 interaction with RIPK3 to promote necroptosis but negatively regulates RIPK1 kinase activity and its interaction with FADD to mediate apoptosis.

Gene References into Functions

De novo splicing variant in MAP3K7 was identified in a patient with cardiospondylocarpofacial syndrome with features of hereditary connective tissue disorder. PMID: 29467388
TAK1 plays a central role in promoting triple-negative breast cancer cell adaptation to the lung microenvironment by facilitating positive feedback signaling mediated by P38. PMID: 29777109
In brief, TAK1 can function as direct AMPK upstream kinase in specific contexts and in response to a subset of TAK1 activating stimuli. Further research is needed to define the intricate signals that are conditional for TAK1 to phosphorylate and activate AMPKalpha at T172. [review] PMID: 30111748
The expression of IL-6 gene and protein was significantly induced by IL-17F. IL-17F activated TAK1 and NF-kappaB in airway smooth muscle cells. PMID: 28474507
overexpression of miR-20a reduced colony formation and tumor growth. Furthermore, the data revealed that the function of miR-20a was probably exerted via targeting the TAK1 expression. Overexpression of miR-20a sensitizes the osteosarcoma cells to chemotherapeutic drugs. PMID: 29327611
TGFbeta and IL1beta signaling interact at the SMAD2/3 level in human primary MSC. Down-stream TGFbeta target genes were repressed by IL1beta independent of C-terminal SMAD2 phosphorylation. We demonstrate that SMAD2/3 linker modifications are required for this interplay and identified TAK1 as a crucial mediator of IL1beta-induced TGFbeta signal modulation. PMID: 28943409
increased TAK1 expression may be involved in the progression of gastric cancer. PMID: 28714004
miR-146a, serving as a tumor suppressor, may significantly promote GC cell apoptosis by inhibition of the NF-kappaB signaling pathway via targeting TAK1. PMID: 28560435
In conclusion, for the first time, we report that TRADD, TRAF2, RIP1 and TAK1 play a role in the regulating TNF-alpha signalling in human myometrium. These findings are of significance given the central role of TNF-alpha in the processes of human labour and delivery. PMID: 28337828
Rab1 is regulated by the host in a similar fashion, and that the innate immunity kinase TAK1 and Legionella effectors compete to regulate Rab1 by switch II modifications during infection. PMID: 27482120
nMet accelerated HCC tumorigenesis and metastasis via the activation of TAK1/NF-kappaB pathway. PMID: 28989054
TAK1 protein expression increased in cartilage tissue from spinal tuberculosis patients. PMID: 28829887
TAK1 regulates Nrf2 through modulation of Keap-p62/SQSTM1 interaction. This regulation is important for homeostatic antioxidant protection in the intestinal epithelium. PMID: 27245349
Overexpression of TAK1 was strongly associated with positive lymph node metastasis in pancreatic ductal adenocarcinoma. PMID: 28194669
dysregulation of the TAK1 complex produces a close phenocopy of Frontometaphyseal Dysplasia caused by FLNA mutations; furthermore, the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex PMID: 27426733
although TAK1 is located at the crossroad of inflammation, immunity, and cancer, this study reports MAP3K7 mutations in a developmental disorder affecting mainly cartilage, bone, and heart PMID: 27426734
This study suggests that aberrant activity of TAK1 impairs autophagy and subsequently leads to alterations in the vitality of retinal pigment epithelial cells. PMID: 26928052
TAK1 may be an important factor involved in the pathogenesis of thyroid cancer, and targeted down-regulation of TAK1 may improve the prognosis of patients with thyroid cancer. PMID: 26823762
Loss of MAP3K7 are associated with esophageal squamous cell carcinoma. PMID: 26406417
This paper highlights that targeting the BMP and TGFbeta type I and type II receptors causes a downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells. PMID: 27048361
Polyubiquitination of Transforming Growth Factor beta-activated Kinase 1 (TAK1) at Lysine 562 Residue Regulates TLR4-mediated JNK and p38 MAPK Activation PMID: 26189595
The data emphasize the central role of TAK1 in controlling signaling cascades and functional responses in primary neutrophils, making it a promising target for therapeutic intervention in view of the role of neutrophils in chronic inflammatory conditions. PMID: 26491199
MiR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells. PMID: 25889255
the TAK1 signaling pathway may represent a suitable target to design new, antifibrotic therapies PMID: 26185333
Findings indicate that SHIP2 is a regulator of lymphatic function in humans and that inherited mutations in the INPPL1 gene may act in concert with HGF, and likely MAP3K7, mutations to exacerbate lymphatic phenotypes. PMID: 25383712
Data indicate that inhibition of TGF-beta-activated protein kinase 1 (TAK1) reduces chemokine (C-C motif) receptor 7 (CCR7) expression. PMID: 25557171
identify coordinate loss of MAP3K7 and CHD1 as a unique driver of aggressive prostate cancer development PMID: 25770290
Data indicate 4-substituted 1H-pyrrolo[2,3-b]pyridines as potent inhibitors against TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). PMID: 25075558
Ubc13 was dispensable for transforming growth factor beta (TGFbeta)-induced SMAD activation but was required for activation of non-SMAD signaling via TGFbeta-activating kinase 1 (TAK1) and p38 PMID: 25189770
Data show that the ECSIT (evolutionarily conserved signaling intermediate in Toll pathways) complex, including MEKK7 (TAK1) and TNF receptor-associated factor 6 (TRAF6), plays a role in Toll-like receptor 4 -mediated signals to activate NF-kappa B. PMID: 25371197
Data suggest a role for the mitogen-activated protein kinase kinase kinase 7 TAK1-jun-NH2-Terminal Kinase JNK pathway as a critical regulator of NLRP3 protein inflammasome activation. PMID: 25288801
Nef markedly activated TAK1 in M-CSF-derived M2-MPhi but not in GM-CSF-derived M1-MPhi. PMID: 24874739
TAK1 may be an important oncogene or an effective target for renal cell carcinoma intervention. PMID: 25261726
TAK1 plays a role in tumor initiation, progression, and metastasis as a tumor prompter or tumor suppressor. An understanding of the role of TAK1 in liver physiology and diseases is required for the development of therapeutic agencies targeting TAK1 PMID: 24443058
Data suggest TAK1 and IKKbeta (inhibitor of kappaB kinase beta) phosphorylate different serines of IKKbeta; TAK1-catalyzed phosphorylation of IKKbeta at Ser177 is priming event that enables IKKbeta to activate itself by phosphorylating Ser181. PMID: 24911653
NLK functions as a pivotal negative regulator of NF-kappaB via disrupting the interaction of TAK1 with IKKbeta. PMID: 24721172
Data indicate that ribosomal S6 kinase 1 (S6K1) is negatively involved in the toll-like receptorS TLR2 and TLR4 signaling pathway by the inhibition of TAK1 (MAP3K7) activity. PMID: 24277938
A dysregulated balance in the activation of TGFbeta-TAK1 and TGFbeta-SMAD pathways is pivotal for TGFbeta1-induced epithelial-mesenchymal transition. PMID: 24113182
Overexpression of TAK1 predicts a poor prognosis in patients with clear cell renal cell carcinoma, so that TAK1 may serve as a novel prognostic marker PMID: 23534745
our study identifies MAP3K7 deletion as a prominent feature in ERG-negative prostate cancer PMID: 23370768
Results establish TAK1 as an AMPKalpha1 kinase that regulates vascular endothelial growth factor-induced and cytokine-induced angiogenesis by modulating SOD2 expression and the superoxide anion:hydrogen peroxide balance. PMID: 24072697
TAK1 (MAP3K7) does not mediate the TGFb-induced phosphorylation of p38 mitogen-activated protein kinases. PMID: 23760366
14-3-3epsilon associates with TAK1 in a phosphorylation-dependent manner to determine the cell fate of Bleomycin-treated HCC cells PMID: 23472066
Two SNPs, rs282070 located in intron 1 of the MAP3K7 gene, and rs2111699 located in intron 1 of the GSTZ1 gene, were significantly associated (after adjustment for multiple testing) with longevity in stage 2 PMID: 22576335
Results indicate that TAK1 and p38 kinases appear to be central in the 'priming effect' of LTB(4) on neutrophils to enhance response to Toll-like receptor ligands. PMID: 22843747
findings suggest that DUSP14 negatively regulates TNF- or IL-1-induced NF-kappaB activation by dephosphorylating TAK1 at Thr-187 PMID: 23229544
TAK1 expression correlates with lymph node metastasis and is a negative, independent prognostic factor in resected T3N1-3M0 ESCCs. PMID: 23272845
TAK1 plays central role in both innate and adaptive immunity as well as in DNA damage, osmotic stress, and hypoxia. (Review) PMID: 22941947
We found that endothelial TAK1 and TAB2, but not TAB1, were critically involved in vascular formation PMID: 22972987
review focuses on current insights into the mechanism and function of the Smad-independent signaling pathway via TGF-beta-activated kinase 1 and its role in mediating the profibrotic effects of TGF-beta1 in chronic kidney disease. [Review Article] PMID: 22835455

Hide All

Involvement in disease

Frontometaphyseal dysplasia 2 (FMD2); Cardiospondylocarpofacial syndrome (CSCF)

Subcellular Location

Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=Although the majority of MAP3K7/TAK1 is found in the cytosol, when complexed with TAB1/MAP3K7IP1 and TAB2/MAP3K7IP2, it is also localized at the cell membrane.

Protein Families

Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase kinase subfamily

Tissue Specificity

Isoform 1A is the most abundant in ovary, skeletal muscle, spleen and blood mononuclear cells. Isoform 1B is highly expressed in brain, kidney and small intestine. Isoform 1C is the major form in prostate. Isoform 1D is the less abundant form.

Database Links

HGNC: 6859

OMIM: 157800

KEGG: hsa:6885

STRING: 9606.ENSP00000358335

UniGene: Hs.594838

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA132828A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: A431 whole cell lysate(30µg), K562 whole cell lysate(30µg), NIH/3T3 whole cell lysate(30µg), Mouse brain tissue lysate(30µg) All lanes: TAK1 antibody at 1:1000 Secondary Goat polyclonal to rabbit IgG at 1/40000 dilution Predicted band size: 67 kDa Observed band size: 75 kDa Exposure time：3min Overlay Peak curve showing 786-O cells stained with CSB-RA132828A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

MAP3K7 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background